Computational prediction and validation of specific EmbR binding site on PknH.

Area of Science:

• Microbiology
• Molecular Biology
• Drug Discovery

Background:

• Tuberculosis (TB) drug resistance poses a significant global health challenge, with unclear molecular underpinnings.
• Ethambutol (EMB) is a first-line TB drug, yet resistance is a growing concern.
• Genetic mutations in Mycobacterium tuberculosis (Mtb) EmbR and EmbC/A/B genes are linked to EMB resistance.

Purpose of the Study:

• To elucidate the molecular mechanisms of EMB resistance in Mtb.
• To identify the specific binding site of the EmbR-PknH interaction.
• To explore novel computer-aided drug discovery approaches for TB.

Main Methods:

• Utilized molecular simulations to analyze EmbR-peptide binding structures.
• Investigated the role of phosphorylated PknH peptides in binding to the EmbR FHA domain.
• Performed hydrogen bond number analysis to confirm molecular recognition features (MoRFs).

Main Results:

• Discovered that phosphorylated PknH 273-280 peptide forms a β-strand with the EmbR FHA domain, acting as a β-MoRF.
• Confirmed EmbR binding affinity to PknH 273-280 through hydrogen bond analysis.
• Identified a potential chronological order for phosphorylation events.

Conclusions:

• The study identified a novel protein-protein interaction site critical for EMB resistance in Mtb.
• This finding provides a new target for developing strategies against drug-resistant TB.
• The computational approach represents a breakthrough in computer-aided drug discovery for identifying interaction sites and binding partners.